



## Hemabate<sup>®</sup> (carboprost tromethamine) – First-time generic

- On July 3, 2019, [Dr. Reddy's launched](#) a generic version of Pfizer's [Hemabate \(carboprost tromethamine\)](#) injection.
  - Hemabate was granted competitive generic therapy by the FDA and will receive 180-days of exclusivity.
- Hemabate is indicated for aborting pregnancy and for the treatment of postpartum hemorrhage.
- According to IQVIA Health, Hemabate had U.S. sales of approximately \$55 million for the 12 month time period ending in April 2019.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.